DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia
Biosciences, Inc.® (Nasdaq: RKDA), a producer and
marketer of innovative, plant-based health and wellness products,
announced it has appointed Kevin
Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief
executive officer, effective January 1,
2022, as the board of directors finalizes its search for a
permanent CEO. As previously announced on September 7, 2021, the board of directors
launched a national search for a new CEO as the company further
expands into the consumer packaged goods (CPG) sector.
Comcowich will continue to serve as board chair, a role he was
appointed to in 2017. He joined the Arcadia board as an independent director in
2016 and previously served as chair of the audit committee.
"This is an exciting time for the company as we are in the final
stages of our search for a permanent CEO to lead the company
forward," said Comcowich. "I'm energized by the impressive work
that's being done to build our portfolio of on-trend, plant-based
food, beverage and body care products."
Matthew Plavan, Arcadia's CEO since 2019, will be departing
the company as of December 31,
2021.
About Arcadia Biosciences, Inc.
With origins as a trailblazing developer of science-based
approaches to enhancing the quality and nutritional value of crops
and food ingredients, Arcadia Biosciences (Nasdaq: RKDA) is now a
producer of innovative, plant-based health and wellness products,
including GoodWheat™, Soul SpringTM,
ProVaultTM, Saavy Naturals® and
Zola® coconut water. The company's growing number
of offerings are designed to enhance quality and health benefits in
an array of consumer product categories. For more information,
visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of
1995, including statements regarding the search for a new CEO.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: Arcadia's and its
partners' and affiliates' ability to develop commercial products
incorporating their traits, and complete the regulatory review
process for such products; customer demand and commercial success
of such products; Arcadia's
compliance with laws and regulations that impact Arcadia's business, including the sale of
products containing CBD, and changes to such laws and regulations;
Arcadia's future capital
requirements and ability to satisfy its capital needs; Arcadia's ability to develop, enforce and
defend its intellectual property rights; and the other risks set
forth in Arcadia's filings with
the Securities and Exchange Commission from time to time, including
the risks set forth in Arcadia's
Annual Report on Form 10-K for the year ended December 31, 2020 and other filings. These
forward-looking statements speak only as of the date hereof, and
Arcadia Biosciences, Inc. disclaims any obligation to update these
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-appoints-kevin-comcowich-to-interim-ceo-301448311.html
SOURCE Arcadia Biosciences, Inc.